Literature DB >> 15923911

A review and analysis of the clinical laboratory improvement amendment of 1988: compliance plans and enforcement policy.

Patrick A Rivers1, Aram Dobalian, Francesco A Germinario.   

Abstract

In 1988, Congress passed the Clinical Laboratory Improvement Amendment (CLIA), thereby extending coverage of the Clinical Laboratory Improvement Act of 1967 to include quality standards for all laboratory-based testing. The CLIA was enacted to ensure the accuracy, reliability, and timeliness of patient test results, regardless of the location where the tests were performed. This article assessed trends in the enforcement policy of the CLIA through an examination of the Laboratory Registry, an annual publication of those individuals or entities that have had sanctions imposed on them by the Centers for Medicare and Medicaid Services. We reviewed the CLIA, including its oversight, regulations that were promulgated based on it, and its enforcement procedures. We obtained the Laboratory Registries for 1993-2001. Sanctions were categorized into groups per the enforcement regulations (42 C.F.R. section sign 493.2 2000). The data indicated an increasing use of more lenient sanctions from 1997 to 2001, and a gradual increase in fraudulent activity for that same period. One possible explanation for this finding is that implementation of compliance plans by participating clinical laboratories had a mitigating effect on enforcement policy. Compliance plan guidance from the OIG provides an opportunity for laboratory service providers to be proactive in their attempts to decrease errors, and thus improve accuracy and reliability by documenting laboratory policies, procedures, and objectives.

Entities:  

Mesh:

Year:  2005        PMID: 15923911     DOI: 10.1097/00004010-200504000-00003

Source DB:  PubMed          Journal:  Health Care Manage Rev        ISSN: 0361-6274


  11 in total

Review 1.  Genetic testing in psychiatry: a review of attitudes and beliefs.

Authors:  Ryan E Lawrence; Paul S Appelbaum
Journal:  Psychiatry       Date:  2011       Impact factor: 2.458

Review 2.  Laboratory results that should be ignored.

Authors:  Dirk M Elston
Journal:  MedGenMed       Date:  2006-10-11

Review 3.  Developing the blueprint for a genetic testing registry.

Authors:  G Javitt; S Katsanis; J Scott; K Hudson
Journal:  Public Health Genomics       Date:  2009-06-29       Impact factor: 2.000

4.  You never call, you never write: why return of 'omic' results to research participants is both a good idea and a moral imperative.

Authors:  Misha Angrist
Journal:  Per Med       Date:  2011-11       Impact factor: 2.512

5.  Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome.

Authors:  Misha Angrist; Subhashini Chandrasekharan; Christopher Heaney; Robert Cook-Deegan
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.864

6.  Additive and Interactive Genetically Contextual Effects of HbA1c on cg19693031 Methylation in Type 2 Diabetes.

Authors:  Kelsey Dawes; Willem Philibert; Benjamin Darbro; Ronald L Simons; Robert Philibert
Journal:  Genes (Basel)       Date:  2022-04-13       Impact factor: 4.141

Review 7.  Interventions to reduce corruption in the health sector.

Authors:  Rakhal Gaitonde; Andrew D Oxman; Peter O Okebukola; Gabriel Rada
Journal:  Cochrane Database Syst Rev       Date:  2016-08-16

Review 8.  No evidence of the effect of the interventions to combat health care fraud and abuse: a systematic review of literature.

Authors:  Arash Rashidian; Hossein Joudaki; Taryn Vian
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

9.  Clinical implementation of RNA signatures for pharmacogenomic decision-making.

Authors:  Weihua Tang; Zhiyuan Hu; Hind Muallem; Margaret L Gulley
Journal:  Pharmgenomics Pers Med       Date:  2011-09-08

10.  Analysis of factors influencing the generation of unqualified clinical samples and measures to prevent this generation.

Authors:  Xiaofei Lai; Ping Yang; Yuhong Zhang; Ju Cao; Liping Zhang
Journal:  Ann Lab Med       Date:  2012-04-18       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.